Opinion statement
No consensus exists regarding optimal systemic treatment for melanoma in the adjuvant or metastatic disease setting. Dendritic cell vaccine therapy, though investigational at present, offers very promising preliminary data that warrant exploration, and patients with existing disease and those seeking adjuvant treatment should evaluate open protocols using this strategy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Faries M, Morton D, Melanoma: Is immunotherapy of benefit?. Advances in Surgery 2003, 37:139–169.
Czerniecki B, Cohen P, Faries M, et al.: Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Critical Rev Immunol 2001, 21:157–178. This is a good review of the spectrum of cell types that fall within the broad classification of dendritic cells as it pertains to vaccine development.
Steinman R, Pope M: Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002, 109:1519–1526.
Rubio V, Stuge T, Singh N, et al.: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003, 9:1377–1382.
Marroquin C, Westwood J, Lapoinet R, et al.: Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother 2002, 25:278–288.
Czerniecki B, Carter C, Rivoltini L, et al.: Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol 1997, 159:3823–3837.
Bedrosian I, Mick R, Xu S, et al.: Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003, 21:3826–3835. This is one of the most recent trial reports that discusses important issues surrounding dendritic cell characteristics, dosing and routes of administration.
National Institute of Health: Comparison of two kinds of dendritic cell immunizations in treating melanoma. Accessible at govhttp://www.clinicaltrials.gov/ct/show/ NCT00001825?order=1. Accessed January 10, 2005.
Mehrotra S, Stevens R, Zengou R, et al.: Regulation of melanoma epitope-specific cytolytic T-lymphocyte response by immature and activated dendritic cells, in vitro. Cancer Res 2003, 63:5607–5614.
Jonuleit H, Schmitt E, Schuler G, et al.: Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000, 192:1213–1222.
Smithers M, O’Connell K, MacFadyen S, et al.: Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 2003, 52:41–52.
Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al.:A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001, 93:243–251.
Nishimura T, Nakui M, Sato M, et al.: The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000, 46(Suppl):S52-S61.
Rissoan M, Soumelis V, Kadowaki N, et al.: Reciprocal control of T-helper cell and dendritic cell differentiation. Science 1999, 283:1124–1125.
Faries M, Bedrosian I, Xu S, et al.: Calcium signaling inhibits interleukin-12 production and activates CD83+ dendritic cells that induce Th2 cell development. Blood 2001, 98:2489–2497.
Riker A, Cormier J, Panelli M, et al.: Immune selection following antigen-specific immunotherapy of melanoma. Surgery 1999, 126:112–120.
Bhardwaj N: Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol Med 2001, 7:388–394.
Schreiber H, Wu T, Nachman J, Kast W: Immunodominance and tumor escape. Semin Cancer Biol 2002, 12:25–31.
Morse M, Nair S, Mosca P, et al.: Immunotherapy with autologous human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003, 21:341–349.
Butterfield L, Jilani S, Chakraborty N, et al.: Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 1998, 161:5607–5613.
Yang S, Kittlesen D, Slingluff C, et al.: Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. J Immunol 2000, 164:4204–4211.
Tatsumi T, Huang J, Gooding W, et al.: Intratumoral delivery of dendritic cells engineered to secrete both interleukin-12 and interleukin-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003, 63:6378–6386.
Albert M, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392:86–89.
Akiyama K, Ebihara S, Yada A, et al.: Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 2003, 170:1641–1648.
Hayashi T, Tanaka H, Tanaka J, et al.: Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 2002, 104:14–20.
Gottfried E, Krieg R, Eichelberg C, et al.: Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immun 2002, 2:15.
Parkhurst M, DePan C, Riley J, et al.: Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 2003, 170:5317–5325.
Butterfield L, Ribas A, Dissette V, et al.: Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003, 9:998–1008.
Schuler-Thurner B, Schultz E, Berger T, et al.: Rapid induction of tumor-specific type 1 T-helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002, 195:1279–1288.
Nestle F, Alijagic S, Gilliet M, et al.: Vaccination of melanoma patients with peptide or tumor lysatepulsed dendritic cells. Nat Med 1998, 4:269–270.
Curtsinger J, Lins D, Mescher M: Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003, 197:1141–1151.
Xu S, Koski G, Faries M, et al.: Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an interleukin-12-dependent mechanism. J Immunol 2003, 171:2251–2261.
Koski GK, Kariko K, Xu S, et al.: Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol 2004, 172:3989–3993.
Lore K, Betts MR, Brenchley JM, et al.: Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T-cell responses. J Immunol 2003, 171:4320–4328.
Hodi FS, Mihm MC, Soiffer RJ, et al.: Biologic activity of cytotoxic T-lymphocyte-associated antigen 4 blockade in previously vaccinated metastatic melanoma and ovarian cancer patients. Proc Natl Acad Sci USA 2003, 100:4712–4717.
Hwu P, Du MX, Lapointe R, et al.: Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T-cell proliferation. J Immunol 2000, 164:3596–3599.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Faries, M.B., Czerniecki, B.J. Dendritic cells in melanoma immunotherapy. Curr. Treat. Options in Oncol. 6, 175–184 (2005). https://doi.org/10.1007/s11864-005-0001-6
Issue Date:
DOI: https://doi.org/10.1007/s11864-005-0001-6